TRAP95 CRISPR/Cas9 KO Plasmid (h): sc-405827
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- TRAP95 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the TRAP95 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: TRAP95 Antibody (F83): sc-130439
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
TRAP95 CRISPR/Cas9 KO Plasmid (h) | sc-405827 | 20 µg | $397.00 |
Overview
MED16 encodes TRAP95, an essential subunit of the Mediator complex that bridges sequence-specific transcription factors with RNA polymerase II to coordinate stimulus-dependent gene expression. TRAP95 contributes to transcriptional regulation programs linked to cell-cycle control, differentiation, and stress-responsive signaling, reflecting its role in integrating multiple upstream pathways at promoters and enhancers. Altered Mediator function, including perturbations of MED16, has been associated with broad transcriptional dysregulation observed in cancer and other disorders of cell identity and homeostasis. As a human nuclear regulatory protein, TRAP95 is commonly studied for its contribution to transcriptional networks and chromatin-associated control of gene expression.
TRAP95 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the MED16 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the MED16 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the MED16 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish TRAP95 protein expression.
This CRISPR knockout system enables efficient generation of MED16-deficient cell models for investigation of TRAP95 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting MED16 exon(s) critical for TRAP95 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple MED16 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by TRAP95 CRISPR/Cas9 KO Plasmid (h) and TRAP95 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the MED16 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by TRAP95 HDR Plasmid (h) and TRAP95 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by MED16 homology arms to support homology-directed repair at defined MED16 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.